Older adults with venous thromboembolism (VTE) reported fewer blood clot complications while using apixaban compared to other ...

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher ...

In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...

The study, known as the Apixaban versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, ...

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial fibrillation, ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...